Temozolomide is effective and well tolerated in patients with primary vitreoretinal lymphoma

Baron et al report excellent responses to temozolomide in 21 patients (19 relapsed/refractory) with primary vitreoretinal lymphoma. Treatment is well tolerated, even in elderly patients.

Saved in:
Bibliographic Details
Published in:Blood 2020-05, Vol.135 (20), p.1811-1815
Main Authors: Baron, Marine, Belin, Lisa, Cassoux, Nathalie, Fardeau, Christine, Blaizeau, Marion, Soussain, Carole, Houillier, Caroline, Hoang-Xuan, Khê, Gyan, Emmanuel, Le Lez, Marie-Laure, Lavaud, Anne, Soubeyran, Pierre, Bodaghi, Bahram, Costopoulos, Myrto, Leblond, Véronique, Touitou, Valérie, Maloum, Karim, Errera, Marie-Hélène, Roos-Weil, Damien, Le Garff-Tavernier, Magali, Choquet, Sylvain
Format: Article
Language:English
Subjects:
Adult
Aged
Aged, 80 and over
Drug-Related Side Effects and Adverse Reactions - epidemiology
Eye Neoplasms - drug therapy
Eye Neoplasms - epidemiology
Eye Neoplasms - pathology
Female
Humans
Lymphoma - drug therapy
Lymphoma - epidemiology
Lymphoma - pathology
Male
Middle Aged
Retinal Neoplasms - drug therapy
Retinal Neoplasms - epidemiology
Retinal Neoplasms - pathology
Retrospective Studies
Temozolomide - therapeutic use
Treatment Outcome
Vitreous Body - pathology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Baron et al report excellent responses to temozolomide in 21 patients (19 relapsed/refractory) with primary vitreoretinal lymphoma. Treatment is well tolerated, even in elderly patients.
ISSN:0006-4971
1528-0020
DOI:10.1182/blood.2019003073